Personalis Price to Free Cash Flow Ratio 2018-2026 | PSNL
Historical price to free cash flow ratio values for Personalis (PSNL) since 2018.
| Personalis Price to Free Cash Flow Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM FCF per Share | Price to FCF Ratio |
| 2026-09-17 | 16.23 | 0.00 | |
| 2026-06-30 | 13.40 | $-1.03 | 0.00 |
| 2026-03-31 | 6.37 | $-0.90 | 0.00 |
| 2025-12-31 | 7.96 | $-0.89 | 0.00 |
| 2025-09-30 | 6.52 | $-0.82 | 0.00 |
| 2025-06-30 | 6.56 | $-0.57 | 0.00 |
| 2025-03-31 | 3.51 | $-0.61 | 0.00 |
| 2024-12-31 | 5.78 | $-0.79 | 0.00 |
| 2024-09-30 | 5.38 | $-0.98 | 0.00 |
| 2024-06-30 | 1.17 | $-1.30 | 0.00 |
| 2024-03-31 | 1.49 | $-1.38 | 0.00 |
| 2023-12-31 | 2.10 | $-1.39 | 0.00 |
| 2023-09-30 | 1.21 | $-1.62 | 0.00 |
| 2023-06-30 | 1.88 | $-2.05 | 0.00 |
| 2023-03-31 | 2.76 | $-2.60 | 0.00 |
| 2022-12-31 | 1.98 | $-2.63 | 0.00 |
| 2022-09-30 | 2.97 | $-2.49 | 0.00 |
| 2022-06-30 | 3.45 | $-2.17 | 0.00 |
| 2022-03-31 | 8.19 | $-2.02 | 0.00 |
| 2021-12-31 | 14.27 | $-1.87 | 0.00 |
| 2021-09-30 | 19.24 | $-1.55 | 0.00 |
| 2021-06-30 | 25.30 | $-1.51 | 0.00 |
| 2021-03-31 | 24.61 | $-1.35 | 0.00 |
| 2020-12-31 | 36.61 | $-1.34 | 0.00 |
| 2020-09-30 | 21.67 | $-1.80 | 0.00 |
| 2020-06-30 | 12.97 | $-0.18 | 0.00 |
| 2020-03-31 | 8.07 | $-1.75 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.687B | $0.070B |
| Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |